01—Abstract
Summary
Summary of the 6-K filed May 21, 2025. Cited figures are marked; the original filing is the authoritative source.
James Hardie Industries plc filed this Form 6-K on May 21, 2025, furnishing its fourth-quarter and full-year FY25 results (year ended 31 March 2025) along with the earnings release, earnings presentation, Appendix 4E, and a KPMG actuarial report on AICF asbestos liabilities.
For FY25, net sales were $3,877.5 milliona, down (1)%, and profit after tax attributable to shareholders was $424.0 million, down (17)%. GAAP operating income was $655.9 million and Adjusted EBITDA was $1,079.4 million, down (4)%, with an Adjusted EBITDA margin of 27.8%. Operating cash flow was $802.8 million, and the company reports no dividend was declared or paid for the period.
For FY26, management guides to North America net sales growth of up low single digits, a North America EBITDA margin of approximately 35.0%, total Adjusted EBITDA growth of up low single digits, and free cash flow of at least $500 millionb, up 30%. Management says it is prudently planning for North American market volumes to contract in FY26. The filing also highlights the proposed acquisition of The AZEK Company Inc., which management expects to close in the second half of calendar 2025 and which is to be funded with a combination of cash and James Hardie shares.
Management cites $500 millionc of run-rate commercial synergies within five years and $125 million of run-rate cost synergies within three years. The company expects to resume share repurchases only after the AZEK transaction closes.
The KPMG actuarial report values the discounted central estimate of asbestos-related liabilities to be met by the AICF Trust at $1,472.4 milliond as at 31 March 2025, compared with $1,457.8 million a year earlier. The report notes that these estimates are subject to considerable uncertainty.
02—Key points
Key Highlights
- FY25 net sales of $3,877.5 million, down (1)%; net profit attributable to shareholders of $424.0 million, down (17)%.
- FY25 Adjusted EBITDA of $1,079.4 million, down (4)%, with an Adjusted EBITDA margin of 27.8%.
- Fourth-quarter net sales of $971.5 million, down (3)%, versus the all-time quarterly record; Q4 Adjusted EBITDA was $268.6 million, down (4)%.
- FY26 guidance: North America net sales up low single digits, North America EBITDA margin of approximately 35.0%, total Adjusted EBITDA up low single digits, and free cash flow of at least $500 million.
- Management is prudently planning for North American market volumes to contract in FY26, including a fourth consecutive year of declines in large-ticket repair & remodel activity.
- Proposed acquisition of The AZEK Company Inc. for a combination of cash and James Hardie shares, expected to close in the second half of calendar 2025; management cites $500 million of run-rate commercial synergies within five years and $125 million of run-rate cost synergies within three years.
- The KPMG actuarial report puts the discounted central estimate of AICF-related asbestos liabilities at $1,472.4 million at 31 March 2025, up from $1,457.8 million a year earlier.
03—Questions
Frequently Asked Questions
How did James Hardie perform financially in fiscal 2025?
Net sales were $3,877.5 million, down (1)%. Profit after tax attributable to shareholders was $424.0 million, down (17)%, and GAAP operating income was $655.9 million. Adjusted EBITDA was $1,079.4 million, down (4)%, with an Adjusted EBITDA margin of 27.8%, and operating cash flow was $802.8 million.
What is the company's outlook for fiscal 2026?
Management expects North America net sales to grow by up low single digits, a North America EBITDA margin of approximately 35.0%, total Adjusted EBITDA growth of up low single digits, and free cash flow of at least $500 million, up 30%. It is planning for North American market volumes to contract in FY26.
What is the proposed AZEK transaction and what are its expected benefits?
James Hardie will acquire The AZEK Company Inc. for a combination of cash and James Hardie shares, with closing expected in the second half of calendar 2025. Management expects $500 million of run-rate commercial synergies within five years, $125 million of run-rate cost synergies within three years, and free cash flow of greater than $1 billion annually once run-rate cost synergies are achieved.
Will the company pay dividends or repurchase shares?
No dividend was proposed or paid for the period. A new repurchase program of up to $300 million runs through October 2025, but the company is not expected to repurchase stock until after the AZEK transaction closes, citing regulatory and other considerations. The company repurchased 4.5 million shares for $150 million during FY25.
What does the KPMG actuarial report indicate about asbestos liabilities?
KPMG valued the discounted central estimate of asbestos-related disease liabilities of the Liable Entities to be met by the AICF Trust at $1,472.4 million as at 31 March 2025, compared with $1,457.8 million at 31 March 2024. The report notes these estimates are subject to considerable uncertainty and that actual outcomes may vary, possibly materially.
04—Continue